BACKGROUND: The metabotropic glutamate receptor 5 noncompetitive antagonist fenobam is analgesic in rodents. Future development of fenobam as an analgesic in humans will require a favorable long-term treatment profile and a lack of significant deleterious side effects. This study aimed to determine whether tolerance to fenobam's analgesic effects developed over 14 days and to assess for side effects in mice. METHODS: Mouse models of pain, locomotor behavior, and coordination were used. Fenobam or vehicle (n = 8 or 11 per group) was administered for 14 days, and analgesic tolerance to fenobam was assessed using the formalin test. Histopathologic examination, hematology, and clinical chemistry analysis after 14-day fenobam administration were also assessed (n = 12 or 9). The effects of fenobam on locomotor activity were assessed in the open field and elevated zero maze (n = 8 or 7). Coordination was assessed using ledge crossing and vertical pole descent tasks (n = 11 or 10). RESULTS: Tolerance to fenobam's analgesic effect did not develop after 14 days. Chronic fenobam administration resulted in statistically significantly less weight gain compared with vehicle control subjects, but did not cause any physiologically or statistically significant hematologic abnormalities, altered organ function, or abnormal histopathology of the liver, brain, or testes. Fenobam administration resulted in a metabotropic glutamate receptor 5-dependent increase in exploratory behavior but does not impair motor coordination at analgesic doses. CONCLUSIONS: Analgesic tolerance to repeat fenobam dosing does not develop. Chronic dosing of up to 14 days is well tolerated. Fenobam represents a promising candidate for the treatment of human pain conditions.
BACKGROUND: The metabotropic glutamate receptor 5 noncompetitive antagonist fenobam is analgesic in rodents. Future development of fenobam as an analgesic in humans will require a favorable long-term treatment profile and a lack of significant deleterious side effects. This study aimed to determine whether tolerance to fenobam's analgesic effects developed over 14 days and to assess for side effects in mice. METHODS:Mouse models of pain, locomotor behavior, and coordination were used. Fenobam or vehicle (n = 8 or 11 per group) was administered for 14 days, and analgesic tolerance to fenobam was assessed using the formalin test. Histopathologic examination, hematology, and clinical chemistry analysis after 14-day fenobam administration were also assessed (n = 12 or 9). The effects of fenobam on locomotor activity were assessed in the open field and elevated zero maze (n = 8 or 7). Coordination was assessed using ledge crossing and vertical pole descent tasks (n = 11 or 10). RESULTS: Tolerance to fenobam's analgesic effect did not develop after 14 days. Chronic fenobam administration resulted in statistically significantly less weight gain compared with vehicle control subjects, but did not cause any physiologically or statistically significant hematologic abnormalities, altered organ function, or abnormal histopathology of the liver, brain, or testes. Fenobam administration resulted in a metabotropic glutamate receptor 5-dependent increase in exploratory behavior but does not impair motor coordination at analgesic doses. CONCLUSIONS: Analgesic tolerance to repeat fenobam dosing does not develop. Chronic dosing of up to 14 days is well tolerated. Fenobam represents a promising candidate for the treatment of humanpain conditions.
Authors: M Storto; U de Grazia; T Knöpfel; P L Canonico; A Copani; P Richelmi; F Nicoletti; M Vairetti Journal: Hepatology Date: 2000-03 Impact factor: 17.425
Authors: Sandeep T Patil; Lu Zhang; Ferenc Martenyi; Stephen L Lowe; Kimberley A Jackson; Boris V Andreev; Alla S Avedisova; Leonid M Bardenstein; Issak Y Gurovich; Margarita A Morozova; Sergey N Mosolov; Nikolai G Neznanov; Alexander M Reznik; Anatoly B Smulevich; Vladimir A Tochilov; Bryan G Johnson; James A Monn; Darryle D Schoepp Journal: Nat Med Date: 2007-09-02 Impact factor: 53.440
Authors: David F Wozniak; Richard E Hartman; Maureen P Boyle; Sherri K Vogt; Ashley R Brooks; Tatyana Tenkova; Chainllie Young; John W Olney; Louis J Muglia Journal: Neurobiol Dis Date: 2004-12 Impact factor: 5.996
Authors: E Berry-Kravis; D Hessl; S Coffey; C Hervey; A Schneider; J Yuhas; J Hutchison; M Snape; M Tranfaglia; D V Nguyen; R Hagerman Journal: J Med Genet Date: 2009-01-06 Impact factor: 6.318
Authors: Vijay K Samineni; Jose G Grajales-Reyes; Gary E Grajales-Reyes; Eric Tycksen; Bryan A Copits; Christian Pedersen; Edem S Ankudey; Julian N Sackey; Sienna B Sewell; Michael R Bruchas; Robert W Gereau Journal: Elife Date: 2021-05-25 Impact factor: 8.140
Authors: Laura F Cavallone; Michael C Montana; Karen Frey; Dorina Kallogjeri; James M Wages; Thomas L Rodebaugh; Tina Doshi; Evan D Kharasch; Robert W Gereau Journal: Pain Date: 2020-01 Impact factor: 7.926
Authors: Rebecca Speltz; Mary M Lunzer; Sarah S Shueb; Eyup Akgün; Rachelle Reed; Alex Kalyuzhny; Philip S Portoghese; Donald A Simone Journal: Pain Date: 2020-09-01 Impact factor: 7.926
Authors: Walter Kostich; Brian D Hamman; Yu-Wen Li; Sreenivasulu Naidu; Kumaran Dandapani; Jianlin Feng; Amy Easton; Clotilde Bourin; Kevin Baker; Jason Allen; Katerina Savelieva; Justin V Louis; Manoj Dokania; Saravanan Elavazhagan; Pradeep Vattikundala; Vivek Sharma; Manish Lal Das; Ganesh Shankar; Anoop Kumar; Vinay K Holenarsipur; Michael Gulianello; Ted Molski; Jeffrey M Brown; Martin Lewis; Yanling Huang; Yifeng Lu; Rick Pieschl; Kevin O'Malley; Jonathan Lippy; Amr Nouraldeen; Thomas H Lanthorn; Guilan Ye; Alan Wilson; Anand Balakrishnan; Rex Denton; James E Grace; Kimberley A Lentz; Kenneth S Santone; Yingzhi Bi; Alan Main; Jon Swaffield; Ken Carson; Sandhya Mandlekar; Reeba K Vikramadithyan; Susheel J Nara; Carolyn Dzierba; Joanne Bronson; John E Macor; Robert Zaczek; Ryan Westphal; Laszlo Kiss; Linda Bristow; Charles M Conway; Brian Zambrowicz; Charles F Albright Journal: J Pharmacol Exp Ther Date: 2016-07-13 Impact factor: 4.030